Lewis, A. C. F. et al. Managing differential performance of polygenic risk scores across groups: real-world experience of the eMERGE network. Am. J. Hum. Genet. 111, 999–1005 (2024).
Lennon, N. J. et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nat. Med. 30, 480–487 (2024).
Jermy, B. et al. A unified framework for estimating country-specific cumulative incidence for 18 diseases stratified by polygenic risk. Nat. Commun. 15, 5007 (2024).
Xiang, R. et al. Recent advances in polygenic scores: translation, equitability, methods and FAIR tools. Genome Med. 16, 33 (2024).
Samani, N. J. et al. Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting. Eur. Heart J. 45, 3152–3160 (2024).
Gibson, G. Going to the negative: genomics for optimized medical prescription. Nat. Rev. Genet. 20, 1–2 (2019).
Gibson, G. On the utilization of polygenic risk scores for therapeutic targeting. PLoS Genet. 15, e1008060 (2019).
Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584–591 (2019).
Wang, Y. et al. Aspiring toward equitable benefits from genomic advances to individuals of ancestrally diverse backgrounds. Am. J. Hum. Genet. 111, 809–824 (2024).
Kachuri, L. et al. Principles and methods for transferring polygenic risk scores across global populations. Nat. Rev. Genet. 25, 8–25 (2024).
Wang, Y., Tsuo, K., Kanai, M., Neale, B. M. & Martin, A. R. Challenges and opportunities for developing more generalizable polygenic risk scores. Annu. Rev. Biomed. Data Sci. 5, 293–320 (2022).
Madden, E. B. et al. Advancing genomics to improve health equity. Nat. Genet. 56, 752–757 (2024).
Nagpal, S., Tandon, R. & Gibson, G. Canalization of the polygenic risk for common diseases and traits in the UK Biobank cohort. Mol. Biol. Evol. 39, msac053 (2022).
Durvasula, A. & Price, A. L. Distinct explanations underlie gene–environment interactions in the UK Biobank. Am. J. Hum. Genet. 112, 644–658 (2025).
Herrera-Luis, E., Benke, K., Volk, H., Ladd-Acosta, C. & Wojcik, G. L. Gene–environment interactions in human health. Nat. Rev. Genet. 25, 768–784 (2024).
Virolainen, S. J., VonHandorf, A., Viel, K. C. M. F., Weirauch, M. T. & Kottyan, L. C. Gene–environment interactions and their impact on human health. Genes Immun. 24, 1–11 (2023).
Marderstein, A. R. et al. Leveraging phenotypic variability to identify genetic interactions in human phenotypes. Am. J. Hum. Genet. 108, 49–67 (2021).
Mostafavi, H. et al. Variable prediction accuracy of polygenic scores within an ancestry group. eLife 9, e48376 (2020).
Hui, D. et al. Risk factors affecting polygenic score performance across diverse cohorts. eLife 12, RP88149 (2025).
Hou, K. et al. Calibrated prediction intervals for polygenic scores across diverse contexts. Nat. Genet. 56, 1386–1396 (2024).
Zhu, C. et al. Amplification is the primary mode of gene-by-sex interaction in complex human traits. Cell Genom. 3, 100297 (2023).
Hermisson, J., Hansen, T. F. & Wagner, G. P. Epistasis in polygenic traits and the evolution of genetic architecture under stabilizing selection. Am. Nat. 161, 708–734 (2003).
Gibson, G. & Lacek, K. A. Canalization and robustness in human genetics and disease. Annu. Rev. Genet. 54, 189–211 (2020).
Gibson, G. Decanalization and the origin of complex disease. Nat. Rev. Genet. 10, 134–140 (2009).
Arnau-Soler, A. et al. Genome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland. Transl. Psychiatry 9, 14 (2019).
Sadowski, M. et al. Characterizing the genetic architecture of drug response using gene–context interaction methods. Cell Genom. 4, 100722 (2024).
Jayasinghe, D. et al. Mitigating type 1 error inflation and power loss in GxE PRS: genotype–environment interaction in polygenic risk score models. Genet. Epidemiol. 48, 85–100 (2024).
Schaid, D. J. et al. Polygenic scores and social determinants of health: their correlations and potential biases. HGG Adv. 6, 100389 (2025).
He, Y. & Patel, C. J. Shared exposure liability of type 2 diabetes and other chronic conditions in the UK Biobank. Acta Diabetol. 59, 851–860 (2022).
Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203–209 (2018).
Weine, E., Smith, S. P., Knowlton, R. K. & Harpak, A. Tradeoffs in modeling context dependency in complex trait genetics. eLife 13, RP99210 (2025).
Inouye, M. et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J. Am. Coll. Cardiol. 72, 1883–1893 (2018).
Isgut, M., Sun, J., Quyyumi, A. A. & Gibson, G. Highly elevated polygenic risk scores are better predictors of myocardial infarction risk early in life than later. Genome Med. 13, 13 (2021).
Fahed, A. C. & Natarajan, P. Clinical applications of polygenic risk score for coronary artery disease through the life course. Atherosclerosis 386, 117356 (2023).
Truong, B. et al. Modification of coronary artery disease clinical risk factors by coronary artery disease polygenic risk score. Med 5, 459–468 (2024).
Ye, Y. et al. Interactions between enhanced polygenic risk scores and lifestyle for cardiovascular disease, diabetes, and lipid levels. Circ. Genom. Precis. Med. 14, e003128 (2021).
Ding, Y. et al. Polygenic scoring accuracy varies across the genetic ancestry continuum. Nature 618, 774–781 (2023).
Urbut, S. M., Wang, G., Carbonetto, P. & Stephens, M. Flexible statistical methods for estimating and testing effects in genomic studies with multiple conditions. Nat. Genet. 51, 187–195 (2019).
Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219–1224 (2018).
McHugh, J. K. et al. Assessment of a polygenic risk score in screening for prostate cancer. N. Engl. J. Med. 392, 1406–1417 (2025).
Cook, R. J. & Sackett, D. L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 310, 452–454 (1995).
Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017).
Ding, Y. et al. Large uncertainty in individual polygenic score estimation impacts PRS-based risk stratification. Nat. Genet. 54, 30–39 (2022).
Westerman, K. E. & Sofer, T. Many roads to a gene–environment interaction. Am. J. Hum. Genet. 111, 626–635 (2024).
Bick, A. G. et al. Genomic data in the All of Us Research Program. Nature 627, 340–346 (2024).
Tsuo, K. et al. All of Us diversity and scale improve polygenic prediction contextually with greatest improvements for under-represented populations. Preprint at bioRxiv https://doi.org/10.1101/2024.08.06.606846 (2024).
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat. Commun. 10, 1776 (2019).
Loh, P.-R. et al. Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance-components analysis. Nat. Genet. 47, 1385–1392 (2015).
Nagpal, S. & Gibson, G. Pervasive interactions between exposures and polygenic risk can inform more effective clinical and behavioral intervention. Zenodo https://doi.org/10.5281/zenodo.20550243 (2026).